Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Curatis News

Aktie
WKN:  A40BDL ISIN:  CH1330780979 Branche:  Pharmazeutika Land:  Schweiz
23,40 CHF
+0,3 CHF
+1,30%
25,450 € 17.04.26
Depot/Watchlist
Marktkapitalisierung *
59,05 Mio. €
Streubesitz
22,26%
KGV
-14,67
Index-Zuordnung
-

Curatis News

24.03.26 - Businesswire
Curatis: Zweistelliges Umsatzwachstum im Jahr 2025 sowie wichtige Meilensteine für Corticorelin erreicht
Die Curatis Holding AG (SIX:CURN, „Curatis“) meldet für 2025 einen Umsatz von 10,8 Mio. CHF (+57 %), und die Curatis AG steigerte den Umsatz ihres Vertriebsgeschäfts organisch ...
24.03.26 - EQS
Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Curatis Holding AG / Key word(s): Annual Results Curatis: Double-​digit revenue growth in 2025 and major milestones for corticorelin achieved 24-March-2026 / 07:00 CET/CEST ...
24.03.26 - Businesswire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from ...
11.03.26 - Businesswire
Curatis und Neupharma geben exklusive Lizenzvereinbarung zur Entwicklung und Vermarktung von Corticorelin (C-PTBE-01) zur Behandlung von peritumoralem Hirnödem in Japan bekannt
Die Curatis Holding AG (SIX: CURN) und Neupharma Co., Ltd. („Neupharma“), ein japanisches Pharmaunternehmen, das sich auf Onkologie, Immunologie, Pulmologie und ...
11.03.26 - EQS
Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in Japan
Curatis Holding AG / Key word(s): Agreement/Partnership Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the ...
11.03.26 - Businesswire
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology ...
21.11.25 - EQS
Curatis Holding AG announces CHF 1.2 million private placement with strategic investor
Curatis Holding AG / Key word(s): Agreement/Financing Curatis Holding AG announces CHF 1.2 million private placement with strategic investor 21-Nov-2025 / 07:00 CET/CEST ...
18.09.25 - EQS
FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3
Curatis Holding AG / Key word(s): Miscellaneous FDA minutes confirm positive outcome of meeting on 9. September 2025 – Corticorelin on track for Phase 3 18.09.2025 / 07:00 ...
15.09.25 - EQS
Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01
Curatis Holding AG / Key word(s): Half Year Results Curatis: Double-​digit growth in core business and development milestone achieved for C-PTBE-01 15-Sep-2025 / 07:00 ...
05.09.25 - EQS
Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Curatis Holding AG / Key word(s): Agreement/Incoming Orders Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues 05.09.2025 / ...
31.07.25 - EQS
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
Curatis Holding AG / Key word(s): Legal Matter/Strategic Company Decision FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study 31.07.2025 / 06:00 CET/CEST
24.05.25 - EQS
Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Curatis Holding AG / Key word(s): AGMEGM Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors 24.05.2025 / 11:31 CET/CEST
23.05.25 - EQS
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billion | Strengthens team with Dr. Kirsty Crame and Dr. Timm Trenktrog
Curatis Holding AG / Key word(s): Change in Forecast/Strategic Company Decision Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE ex...

Newssuche

Videos

newspaper
16.04.26 +2,80%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »